At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 41 enrolled
Drug / intervention
topical desonide hydrogel 0.05%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis
In Brief
A Phase 4 clinical trial evaluating topical desonide hydrogel 0.05% for Atopic Dermatitis. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionDec 2007
First PostedJun 2008
Study CompletionNov 2009
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartAug 1, 2007
Primary CompletionDec 1, 2007
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.1 years ago
Interventions
topical desonide hydrogel 0.05%drug
apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions